Journal of Urban Health

, Volume 90, Issue 2, pp 276–283

Pharmacy Syringe Purchase Test of Nonprescription Syringe Sales in San Francisco and Los Angeles in 2010

  • Alexandra Lutnick
  • Erin Cooper
  • Chaka Dodson
  • Ricky Bluthenthal
  • Alex H. Kral
Article

Abstract

The two main legal sources of clean needles for illicit injection drug users (IDUs) in California are syringe exchange programs (SEPs) and nonprescription syringe sales (NPSS) at pharmacies. In 2004, California became one of the last states to allow NPSS. To evaluate the implementation of NPSS and the California Disease Prevention Demonstration Project (DPDP), we conducted syringe purchase tests in San Francisco (SF) and Los Angeles (LA) between March and July of 2010. Large differences in implementation were observed in the two cities. In LA, less than one-quarter of the enrolled pharmacies sold syringes to our research assistant (RA), and none sold a single syringe. The rate of successful purchase in LA is the lowest reported in any syringe purchase test. In both sites, there was notable variation among the gauge size available, and price and quantity of syringes required for a purchase. None of the DPDP pharmacies in LA or SF provided the requisite health information. The findings suggest that more outreach needs to be conducted with pharmacists and pharmacy staff. The pharmacies' failure to disseminate the educational materials may result in missed opportunities to provide needed harm reduction information to IDUs. The varied prices and required quantities may serve as a barrier to syringe access among IDUs. Future research needs to examine reasons why pharmacies do not provide the mandated information, whether the omission of disposal options is indicative of pharmacies' reluctance to serve as disposal sites, and if the dual opt-in approach of NPSS/DPDP is a barrier to pharmacy enrollment.

Keywords

Nonprescription syringe sales IDU SB1159 California Pharmacy Policy 

References

  1. 1.
    Injection drug users and their sex/needle sharing partners. Sacramento: Office of AIDS, California Department of Public Health; September 2007.Google Scholar
  2. 2.
    Alter MJ, Margolis HS, Bell BP, et al. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR. 1998; 47(RR19): 1–36.Google Scholar
  3. 3.
    Rodgers AB, Jones S, Abdul-Quader A, et al. New attitudes and strategies: a comprehensive approach to preventing blood-borne infections among IDUs. Atlanta, GA: Centers for Disease Control and Prevention; 2000.Google Scholar
  4. 4.
    Gayle HD, O'Neill JF, Gust SW, Mata A. HIV Prevention bulletin: medical advice for persons who inject illicit drugs. Atlanta, GA: US Department of Health and Human Services; 1997.Google Scholar
  5. 5.
    Bluthenthal RN, Heinzerling KG, Anderson R, Flynn NM, Kral AH. Approval of syringe exchange programs in California: results from a local approach to HIV prevention. Am J Public Health. 2008; 98(2): 278–283.PubMedCrossRefGoogle Scholar
  6. 6.
    Stopka TJ, Garfein RS, Ross A, Truax SR. Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel. J Urban Health. 2007; 84(1): 116–125.PubMedCrossRefGoogle Scholar
  7. 7.
    Garfein RS, Stopka TJ, Pavlinac PB, et al. Three years after legalization of nonprescription pharmacy syringe sales in California: where are we now? J Urban Health. 2010; 87(4): 576–585.PubMedCrossRefGoogle Scholar
  8. 8.
    Cleland CM, Deren S, Fuller CM, et al. Syringe disposal among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. Health Educ Behav. 2007; 34(2): 390–403.PubMedCrossRefGoogle Scholar
  9. 9.
    Singer M, Baer HA, Scott G, Horowitz S, Weinstein B. Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut. Public Health Rep. 1998; 113(Suppl 1): 81–89.PubMedGoogle Scholar
  10. 10.
    Fuller CM, Galea S, Caceres W, Blaney S, Sisco S, Vlahov D. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health. 2007; 97(1): 117–124.PubMedCrossRefGoogle Scholar
  11. 11.
    Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. J Acquir Immune Defic Syndr. 2005; 39(4): 471–477.PubMedCrossRefGoogle Scholar
  12. 12.
    Rich JD, Hogan JW, Wolf F, et al. Lower syringe sharing and re-use after syringe legalization in Rhode Island. Drug Alcohol Depend. 2007; 89(2–3): 292–297.PubMedCrossRefGoogle Scholar
  13. 13.
    Friedman SR, Perlis T, Des Jarlais DC. Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health. 2001; 91(5): 791–793.PubMedCrossRefGoogle Scholar
  14. 14.
    Deren S, Cleland CM, Fuller C, Kang SY, Des Jarlais DC, Vlahov D. The impact of syringe deregulation on sources of syringes for injection drug users: preliminary findings. AIDS Behav. 2006; 10(6): 717–721.PubMedCrossRefGoogle Scholar
  15. 15.
    Deibert RJ, Goldbaum G, Parker TR, et al. Increased access to unrestricted pharmacy sales of syringes in Seattle-King County, Washington: structural and individual-level changes, 1996 versus 2003. Am J Public Health. 2006; 96(8): 1347–1353.PubMedCrossRefGoogle Scholar
  16. 16.
    Farley TA, Niccolai LM, Billeter M, Kissinger PJ, Grace M. Attitudes and practices of pharmacy managers regarding needle sales to injection drug users. J Am Pharm Assoc (Wash). 1999; 39(1): 23–26.Google Scholar
  17. 17.
    Blumenthal W, Springer K, Jones S, Stark C. Pharmacy student knowledge, attitudes and beliefs about selling syringes to injection drug users. J Am Pharm Assoc. 2002; 42(6): S34–S39.Google Scholar
  18. 18.
    Taussig J, Junge B, Burris S, Jones TS, Sterk CE. Individual and structural influences shaping pharmacists' decisions to sell syringes to injection drug users in Atlanta, Georgia. J Am Pharm Assoc (Wash). 2002; 42(6 Suppl 2): S40–S45.CrossRefGoogle Scholar
  19. 19.
    Kral AH, Garfein RS. Evaluating a statewide pilot syringe access program for injection drug users through pharmacies in California. J Urban Health. 2010; 87(4): 531–533.PubMedCrossRefGoogle Scholar
  20. 20.
    Cooper EN, Dodson C, Stopka TJ, Riley ED, Garfein RS, Bluthenthal RN. Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco counties, 2007. J Urban Health. 2010; 87(4): 543–552.PubMedCrossRefGoogle Scholar
  21. 21.
    Rose VJ, Raymond HF. Evaluation of nonprescription syringe sales in San Francisco. J Am Pharm Assoc. 2010; 50(5): 595–599.CrossRefGoogle Scholar
  22. 22.
    Compton W, Horton J, Cottler L, et al. A multistate trial of pharmacy syringe purchase. J Urban Health. 2004; 81(4): 661–670.PubMedCrossRefGoogle Scholar
  23. 23.
    Finkelstein R, Tiger R, Greenwald R, Mukherjee R. Pharmacy syringe sale practices during the first year of expanded syringe availability in New York City (2001–2002). J Am Pharm Assoc. 2002; 42(Supplement 1): S83–S87.Google Scholar
  24. 24.
    Trubatch BN, Fisher DG, Cagle HH, Fenaughty AM, Johnson ME. Nonprescription pharmacy sales of needles and syringes. Am J Public Health. 2000; 90(10): 1639–1640.PubMedCrossRefGoogle Scholar
  25. 25.
    Koester SK, Bush TW, Lewis BA. Limited access to syringes for injection drug users in pharmacies in Denver, Colorado. J Am Pharm Assoc (Wash). 2002; 42(6 Suppl 2): S88–S91.CrossRefGoogle Scholar
  26. 26.
    Riley ED, Kral AH, Stopka TJ, Garfein RS, Reuckhaus P, Bluthenthal RN. Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users. J Urban Health. 2010; 87(4): 534–542.PubMedCrossRefGoogle Scholar

Copyright information

© The New York Academy of Medicine 2012

Authors and Affiliations

  • Alexandra Lutnick
    • 1
  • Erin Cooper
    • 2
  • Chaka Dodson
    • 2
  • Ricky Bluthenthal
    • 3
  • Alex H. Kral
    • 1
  1. 1.Urban Health Program, RTI InternationalSan FranciscoUSA
  2. 2.Urban Community Research CenterCalifornia State University Dominguez HillsCarsonUSA
  3. 3.Department of Preventive Medicine, Institute for Prevention Research, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations